Physician profile
Christopher B Lynch
NPI 1952307456
$48,245.81
in general payments reported to CMS, 2019-2025
21 companies · $390 in 2025
The $390 reported for 2025 was less than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $8,547 · 2021: $12K · 2022: $2,453 · 2023: $2,051 · 2024: $800 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,732 · Food and Beverage: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,732.00 |
| Food and Beverage | $509.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| B. Braun Medical INC. | $22,535.74 | 2019-2024 | |
| Orthalign INC | $16,890.51 | 2019-2021 | |
| Medacta USA, INC. | $2,401.35 | 2020-2023 | Gmk Sphere |
| Depuy Synthes Products, INC. | $2,047.53 | 2022 | |
| Smith+Nephew, INC. | $1,912.07 | 2019 | |
| Depuy Synthes Sales INC. | $619.18 | 2019-2025 | Monovisc, Orthovisc, Peak |
| Horizon Therapeutics Plc | $444.01 | 2019-2021 | |
| Pacira Therapeutics, INC. | $401.99 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $202.01 | 2025 | Arcos |
| Davol INC. | $158.60 | 2022 | |
| Medical Device Business Services, INC. | $138.09 | 2019 | |
| Globus Medical, INC. | $107.50 | 2019 | |
| Ferring Pharmaceuticals INC. | $91.82 | 2022-2025 | Euflexxa |
| Vertos Medical, INC. | $74.85 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $57.73 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $40.00 | 2019 | |
| Endo Pharmaceuticals INC. | $31.46 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $28.52 | 2025 | Exparel, Iovera, Zilretta |
| Boston Scientific Corporation | $23.02 | 2021 | |
| Sanofi-Aventis U.S. LLC | $22.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.